Formycon AG Schedules Conference Call for 2025 Results and Investor Engagement

Formycon AG, a leading developer of biosimilars, has announced a conference call to discuss its Nine-Month financial results for 2025. Scheduled for November 13, 2025, at 3:00 PM CET, the call will cover company developments, key financials, and the outlook for the rest of the year. Participants can register online to access the live broadcast and post-call recordings.

Additionally, Formycon's Management Board will engage with the investment community by participating in several conferences during Q4 2025. These include the Jefferies Global Healthcare Conference in London and the Deutsche Börse Equity Forum in Frankfurt. Such events aim to bolster investor relations and showcase the company's strategic directions.

Headquartered in Munich, Formycon AG remains a vital player in the pharmaceuticals sector, focusing on accessible and effective healthcare solutions through the development and commercialization of high-quality biosimilars. As of now, the company successfully markets two biosimilars and has another approved by global health authorities.